Trial Profile
Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis. A Non-interventional Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Rivaroxaban (Primary)
- Indications Acute coronary syndromes; Arterial thrombosis; Atherosclerosis; Cardiovascular disorders; Coronary artery disease; Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms XATOA
- Sponsors Bayer
- 23 May 2022 According to a Janssen Pharmaceutical Media Release, results from open label extension part have been published in the European Society of Cardiology's (ESC) European Heart Journal, Cardiovascular Pharmacotherapy.Additionally, the XATOA registry was presented at the American Congress of Cardiology's 71st Annual Scientific Session (ACC.22).
- 23 May 2022 Results published in the Janssen Pharmaceutical Media Release
- 03 Aug 2021 Status changed from active, no longer recruiting to completed.